{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-003166","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.804088+00:00","generated_at":"2026-05-28T01:57:28.695726+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"NeuroOne issues shareholder letter; no specific financial or operational metrics disclosed","bullets":["CEO Dave Rosa discusses company achievements, progress, and strategy in letter dated Jan 14, 2025.","Letter does not contain specific revenue, earnings, or guidance figures.","Letter posted to company website and furnished under Regulation FD.","No material new information beyond general business update."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-003166","json":"https://secwatch.observer/filing/0001213900-25-003166.json","markdown":"https://secwatch.observer/filing/0001213900-25-003166.md","text":"https://secwatch.observer/filing/0001213900-25-003166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025003166/0001213900-25-003166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025003166/ea0227550-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:57:28.695726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}